Science | 09 January 2025 | News
Specific brain regions drive chemotherapy-induced pain response: IISc study
Chronic physical pain can be debilitating, but feelings of stress, fear, and hunger can sometimes suppress pai...Read more
Telangana | 31 December 2024 | Interviews
What key initiatives and strategic changes is the Telangana government implementing to attract investments in ...Read more
MedTech | 13 January 2025 | News
Stryker launches Insignia Hip Stem for total hip and hemiarthroplasty procedures in India
Stryker, a global leader in medical technologies, has announced the launch of its Insignia Hip Stem in In...Read more
West Bengal | 08 January 2025 | News
Global Cloud Cayr launches health management services in Kolkata
Global Cloud Cayr (GCC), an innovative healthcare startup founded by an international team of doctors and...Read more
Supplier | 09 January 2025 | News
Bruker launches infrared imaging microscope for pharma and life science research
US-based Bruker Corporation has announced the launch of the LUMOS II ILIM, a quantum cascade la...Read more
People | 09 January 2025 | News
Medanta appoints leading urologist Dr Sanjay Gogoi as Chairman of Renal Care Institute
Reinforcing its leadership in advanced kidney care and transplantation, Medanta has appointed globally renowne...Read more
Academics | 14 January 2025 | News
Tata Group and IISc partner to establish medical school to pioneer healthcare education
The Tata Group has announced a partnership with the Indian Institute of Science (IISc) to estab...Read more
Text blogs | 31 December 2024 | Views
Key Skills & Salary Trends in Healthcare & Pharma for 2025
Evolving Skillsets The healthcare and pharmaceutical industries are undergoing profound transformations...Read more
Indian Pharma Hits R&D Salvo
Pharma companies are constantly on the quest to discover the next big game-changer drug or therapeutic by leveraging the latest, cutting-edge innovation. While it is notable that biopharma companies eased up on their research and development (R&D) spending in FY 2022-23 after the world was hit by COVID-19- induced economic slowdown, the budget for R&D has witnessed a steady increase. Departing a bit from their traditional drug portfolios, companies are increasingly focusing on R&D in nextgeneration therapies to drive innovation, particularly in complex generics, biosimilars, cell and gene therapies and novel drug delivery systems.
For Feedback, please email us at: communications@mmactiv.com